FrancophonIA/ELRC3.0 huggingface dataset:
English: Pritor 80 mg tablets
Estonian: Pritor 80 mg tabletid
English: Pritor 20 mg tablets
Estonian: Pritor 20 mg tabletid
English: Pritor is available in blister packs containing 14, 28, 30, 56, 90, 98 or 280 tablets, or unit dose blister packs containing 28 x 1 tablets.
Estonian: Pritor'it müüakse blisterpakendites, milles paikneb 14, 28, 30, 56, 90, 98 või 280 tabletti, või augustatud ühikannuse 28 x 1 tableti blisterites.
English: The active substance is telmisartan.
Estonian: Mida Pritor sisaldab - Toimeaine on telmisartaan.
English: What Pritor looks like and contents of the pack Pritor 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side.
Estonian: Pritor 20 mg tabletid on valged, ümmmargused ning mille ühele küljele on graveeritud kood 50H ja teisele küljele firma logo.
English: What Pritor contains
Estonian: Kuidas Pritor välja näeb ja pakendi sisu
English: Bayer AG Kaiser-Wilhelm-Allee 51368 Leverkusen Germany
Estonian: Müügiloa hoidja Bayer AG 51368 Leverkusen Saksamaa
English: Each 20 mg tablet contains 84 mg sorbitol (E420).
Estonian: Teadaolevat toimet omavad abiained Iga 20 mg tablett sisaldab 84 mg sorbitooli (E420).
English: Tabulated list of adverse reactions
Estonian: Valikuliste kõrvaltoimete kirjeldus
English: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan.
Estonian: Liitiumi samaaegsel kasutamisel angiotensiini konverteeriva ensüümi inhibiitoritega - ja ka angiotensiin-II retseptori antagonistidega, k.a telmisartaaniga - on täheldatud liitiumi kontsentratsiooni pöörduvat tõusu seerumis ja tema toksilisuse suurenemist.
English: Therefore, in these patients an appropriate blood glucose monitoring should be considered; a dose adjustment of insulin or antidiabetics may be required, when indicated.
Estonian: Seetõttu tuleb sellistel patsientidel kaalutleda adekvaatset vereglükoosi taseme jälgimist.
English: Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema); these side effects are rare may affect up to 1 in 1,000 people) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
Estonian: Sepsis* (sageli nimetatakse “veremürgistus”, mis on raskekujuline infektsioon kogu organismi põletikulise reaktsiooniga), naha ja limaskestade kiire tursumine (angioödeem).
English: NAME OF THE MEDICINAL PRODUCT Pritor 20 mg tablets
Estonian: RAVIMPREPARAADI NIMETUS Pritor 20 mg tabletid
English: NAME OF THE MEDICINAL PRODUCT Pritor 40 mg tablets telmisartan
Estonian: RAVIMPREPARAADI NIMETUS Pritor 40 mg tabletid Telmisartaan
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 40 mg telmisartan.
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 40 mg telmisartaani.
English: Bayer OÜ Tel: +372 655 85 65
Estonian: Tel: +372 655 85 65
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 20 mg telmisartan.
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 20 mg telmisartaani.
English: Tell your doctor if you are breast-feeding or about to start breast-feeding.
Estonian: Teatage oma arstile, kui imetate last või kavatsete seda teha.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 80 mg telmisartan.
Estonian: TOIMEAINE(TE) SISALDUS Iga tablett sisaldab 80 mg telmisartaani.
English: Volume and/or sodium depletion should be corrected prior to administration of Pritor.
Estonian: Enne Pritor'i manustamist tuleb hüpovoleemia/hüponatreemia korrigeerida.
English: EU/1/98/089/011 (14 tablets) EU/1/98/089/012 (28 tablets) EU/1/98/089/020 (30 tablets) EU/1/98/089/013 (56 tablets) EU/1/98/089/019 (90 tablets) EU/1/98/089/014 (98 tablets)
Estonian: EU/1/98/089/011 (14 tabletti) EU/1/98/089/012 (28 tabletti) EU/1/98/089/020 (30 tabletti) EU/1/98/089/013 (56 tabletti) EU/1/98/089/019 (90 tablets) EU/1/98/089/014 (98 tabletti)
English: EU/1/98/089/006 (14 tablets) EU/1/98/089/007 (28 tablets) EU/1/98/089/022 (30 tablets) EU/1/98/089/008 (56 tablets) EU/1/98/089/018 (90 tablets) EU/1/98/089/009 (98 tablets) EU/1/98/089/010 (280 tablets) EU/1/98/089/016 (28 x 1 tablets)
Estonian: EU/1/98/089/006 (14 tabletti) EU/1/98/089/007 (28 tabletti) EU/1/98/089/022 (30 tabletti) EU/1/98/089/008 (56 tabletti) EU/1/98/089/018 (90 tabletti) EU/1/98/089/009 (98 tabletti) EU/1/98/089/010 (280 tabletti) EU/1/98/089/016 (28 x 1 tablett)
English: Urinary tract infection including cystitis, upper respiratory tract infection including pharyngitis and sinusitis, Sepsis including fatal outcome
Estonian: Kuseteede infektsioonid, sh põiepõletik, ülemiste hingamisteede infektsioon, sh farüngiit ja sinuiit
English: NAME OF THE MEDICINAL PRODUCT Pritor 80 mg tablets telmisartan
Estonian: RAVIMPREPARAADI NIMETUS Pritor 80 mg tabletid Telmisartaan
English: NAME OF THE MEDICINAL PRODUCT Pritor 20 mg tablets telmisartan
Estonian: RAVIMPREPARAADI NIMETUS Pritor 20 mg tabletid Telmisartaan
English: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia, dizziness, increase in serum creatinine, and acute renal failure have also been reported.
Estonian: Samuti on registreeritud bradükardiat, pearinglust, kreatiniini kontsentratsiooni tõusu seerumis ning ägedat neerupuudulikkust.
English: Reduction of the antihypertensive effect.
Estonian: Kortikosteroidid (süsteemselt) Antihüpertensiivse toime vähenemine.
English: Sepsis* (often called "blood poisoning " is a severe infection with whole-body inflammatory response which can lead to death), increase in certain white blood cells (eosinophilia), low platelet count (thrombocytopenia), severe allergic reaction (anaphylactic reaction), allergic reaction (e.g. rash, itching, difficulty breathing, wheezing, swelling of the face or low blood pressure), low blood sugar levels (in diabetic patients), feeling anxious, somnolence, impaired vision, fast heart beat (tachycardia), dry mouth, upset stomach, taste disturbance (dysgeusia), abnormal liver function (Japanese patients are more likely to experience this side effect), rapid swelling of the skin and mucosa which can also lead to death (angioedema also with fatal outcome), eczema (a skin disorder), redness of skin, hives (urticaria), severe drug rash, joint pain (arthralgia), pain in extremity, tendon pain, flu-like-illness, decreased haemoglobin (a blood protein), increased levels of uric acid, increased hepatic enzymes or creatine phosphokinase in the blood.
Estonian: Sepsis* (sageli nimetatakse “veremürgistuseks”, mis on kogu organismi põletikulise reaktsiooniga kulgev raske infektsioon ja mis võib lõppeda surmaga), teatavate vere valgeliblede arvu tõus (eosinofiilia), vereliistakute arvu vähesus (trombotsütopeenia), raske allergiline reaktsioon (anafülaktiline reaktsioon), allergiline reaktsioon (nt lööve, sügelus, hingamisraskus, kähisev hingamine, näo turse või madal vererõhk), madal veresuhkru kontsentratsioon (suhkruhaigetel), ärevus, nägemishäire, südame löögisageduse kiirenemine (tahhükardia), suukuivus, seedehäired, maitsetundlikkuse häired (düsgeusia), maksafunktsiooni häire (Jaapani patsientidel võib suurema tõenäosusega esineda see kõrvaltoime), naha ja limaskestade järsk turse, mis võib lõppeda ka surmaga (samuti letaalse lõppega angioödeem), ekseem (naha häire), naha punetus, nõgestõbi (urtikaaria), raskekujuline ravimlööve, liigesvalu (artralgia), jäsemevalu, kõõlusvalu, gripitaoline haigus, hemoglobiini (verevalgu) taseme langus, kusihappe taseme tõus veres, maksaensüümide aktiivsuse tõus või kreatiinfosfokinaasi taseme tõus veres.
English: Pritor should be used only with caution in patients with mild to moderate hepatic impairment.
Estonian: Kerge või keskmise raskusega maksapuudulikkust põdevatel patsientidel tuleb Pritor'it kasutada ettevaatusega.
English: EU/1/98/089/001 (14 tablets) EU/1/98/089/002 (28 tablets) EU/1/98/089/021 (30 tablets) EU/1/98/089/003 (56 tablets) EU/1/98/089/017 (90 tablets) EU/1/98/089/004 (98 tablets) EU/1/98/089/005 (280 tablets) EU/1/98/089/015 (28 x 1 tablets)
Estonian: Pritor 40 mg tabletid EU/1/98/089/001 (14 tabletti) EU/1/98/089/002 (28 tabletti) EU/1/98/089/021 (30 tabletti) EU/1/98/089/003 (56 tabletti) EU/1/98/089/017 (90 tablets) EU/1/98/089/004 (98 tabletti) EU/1/98/089/005 (280 tabletti) EU/1/98/089/015 (28 x 1 tablett)
English: Paediatric population
Estonian: Gripitaoline haigus
English: Urinary tract infections, upper respiratory tract infections (e.g. sore throat, inflamed sinuses, common cold), deficiency in red blood cells (anaemia), high potassium levels, difficulty falling asleep, feeling sad (depression), fainting (syncope), feeling of spinning (vertigo), slow heart rate (bradycardia), low blood pressure (hypotension) in users treated for high blood pressure, dizziness on standing up (orthostatic hypotension), shortness of breath, cough, abdominal pain, diarrhoea, discomfort in the abdomen, bloating, vomiting, itching, increased sweating, drug rash, back pain, muscle cramps, muscle pain (myalgia), kidney impairment including acute kidney failure, pain in the chest, feeling of weakness, and increased level of creatinine in the blood.
Estonian: Kuseteede infektsioonid; ülemiste hingamisteede infektsioonid (nt kurguvalu, põskkoobaste põletik, nohu); vere punaliblede vähesus (aneemia); kaaliumi taseme tõus veres; uinumisraskus; meeleolu langus (depressioon); minestamine (sünkoop); peapööritus (vertiigo); südame löögisageduse aeglustumine (bradükardia); madal vererõhk (hüpotensioon) patsientidel, keda ravitakse kõrgvererõhu tõve tõttu; pearinglus püsti tõusmisel (ortostaatiline hüpotensioon); õhupuudus; köha; kõhuvalu; kõhulahtisus; ebamugavustunne kõhus; kõhupuhitus; oksendamine; sügelus; suurenenud higistamine; ravimlööve; seljavalu; lihaskrambid; lihasvalu (müalgia); neerukahjustus, sh äge neerupuudulikkus; valu rinna piirkonnas; nõrkustunne ja kreatiniini taseme tõus veres.
English: Symptomatic hypotension, especially after the first dose of Pritor, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting.
Estonian: Tugeva diureetilise raviga, keedusoola tarvitamise märgatava piiranguga või kõhulahtisuse või oksendamisega haiged, kellel on selle tagajärjel välja kujunenud hüpovoleemia/hüponatreemia, on Pritor'i kasutamisel ohustatud sümptomaatilisest hüpotensioonist, eriti pärast esimest Pritor'i annust.
English: Hepatic function abnormal / liver disorder
Estonian: Maksafunktsiooni kõrvalekalle / maksa häire
English: What Pritor looks like and contents of the pack Pritor 80 mg tablets are white, oblong-shaped and engraved with the code '52H' on one.
Estonian: Pritor 80 mg tabletid on valged, pikliku-kujuga ning mille ühele küljele on graveeritud kood 52H.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Insuman on 21 February 1997.
Estonian: Euroopa Komisjon andis Insumani müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. veebruaril 1997.
English: The full EPAR for Insuman can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Insumani kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Insuman should be given before meals.
Estonian: Insumani peab süstima enne sööki.
English: The pump must not be implanted in people who reside permanently at elevations above at elevations above 2,439 metres (8000 feet).
Estonian: Pumpa ei tohi implanteerida ka patsientidele, kelle püsiv elukoht asub kõrgemal kui 2439 meetrit (8000 jalga) merepinnast.
English: Insuman human insulin
Estonian: Insuman iniminsuliin
English: What is Insuman?
Estonian: Mis on Insuman?
English: The Committee recommended that Insuman be given marketing authorisation.
Estonian: Komitee soovitas anda Insumani müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Insuman.
Estonian: See on ravimi Insuman Euroopa avaliku hindamisaruande kokkuvõte.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Insuman.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Why has Insuman been approved?
Estonian: Miks Insuman heaks kiideti?
English: By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.
Estonian: Vere glükoosisisalduse reguleerimisega vähenevad diabeedi sümptomid ja tüsistused.
English: Insuman may cause hypoglycaemia.
Estonian: Insuman võib põhjustada hüpoglükeemiat.
English: The desired blood glucose levels, the type of Insuman to be used, and the dose and timing of injections are determined by the doctor for each patient individually, and are adjusted to suit the patient's diet, physical activity and lifestyle.
Estonian: Vajaliku glükoosisisalduse veres, kasutatava Insumani liigi, annuse ja süste ajastamise määrab kindlaks arst iga patsiendi puhul eraldi ning kohandab neid vastavalt patsiendi dieedile, kehalisele aktiivsusele ja elustiilile.
English: Insuman contains insulin in various forms: the soluble form, which acts quickly (within 30 minutes of injection), and the isophane and crystalline-protamine forms, which are absorbed much more slowly during the day, giving them a longer duration of action.
Estonian: Insuman sisaldab insuliini eri kujul: lahustuvat insuliini, mis toimib kiiresti (30 minuti jooksul pärast süstimist), ning isofaaninsuliini ja kristallilist protamiininsuliini, mis imenduvad tunduvalt aeglasemalt ööpäeva jooksul, kuid mille toime kestab pikemat aega.
English: Insuman Rapid may also be given into a vein, but only in an intensive care unit or similar setting where the patient can be closely monitored.
Estonian: Insuman Rapidit tohib manustada ka intravenoosselt (veeni), kuid ainult intensiivraviosakonnas või sarnastes tingimustes, kus patsienti on võimalik pidevalt jälgida.
English: For more information about treatment with Insuman, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Insumaniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Insuman
Estonian: Muu teave Insumani kohta
English: Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose (type 1 diabetes) or when the body is unable to use insulin effectively (type 2 diabetes).
Estonian: Diabeet (suhkurtõbi) on haigus, mille korral organismis ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini (I tüüpi diabeet) või organism ei suuda insuliini efektiivselt kasutada (II tüüpi diabeet).
English: Insuman has been studied in three trials in 780 patients with either type 1 diabetes or type 2 diabetes.
Estonian: Insumani uuriti kolmes uuringus, milles osales kokku 780 I või II tüüpi diabeediga patsienti.
English: The active substance in Insuman, human insulin, is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced that makes the bacteria able to produce insulin.
Estonian: Insumani toimeainet iniminsuliini valmistatakse rekombinant-DNA-tehnika abil: seda toodavad bakterid, millesse on viidud insuliini teket võimaldav geen (DNA).
English: Insuman Rapid, Infusat, Basal and Comb are given by injection under the skin, generally in the abdominal wall (tummy) or the thigh, according to the doctor's recommendations.
Estonian: Ravimeid Insuman Rapid, Infusat, Basal ja Comb süstitakse naha alla enamasti kõhueesseina või reide vastavalt arsti soovitustele.
English: Insuman Implantable must not be used in any other way and can only be used in centres where staff have received adequate training in the use of the implantable pump.
Estonian: Ravimit Insuman Implantable ei tohi kasutada mingil muul viisil ning seda tohib manustada ainult tervishoiukeskustes, mille töötajad on saanud implanteeritava pumba kasutamise väljaõppe.
English: For the full list of all side effects reported with Insuman, see the Package Leaflet.
Estonian: Insumani kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is the risk associated with Insuman?
Estonian: Mis riskid Insumaniga kaasnevad?
English: The replacement insulin acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Estonian: Asendusinsuliin toimib samal viisil kui organismis teel tekkiv insuliin, aidates glükoosil siseneda verest rakkudesse.
English: Insuman led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with semi-synthetic human insulin.
Estonian: Insuman vähendas HbA1c sisaldust, mis näitab, et ravim reguleeris vere glükoosisisaldust sarnasel määral kui poolsünteetiline iniminsuliin.
English: No other insulins must be used with the pump and the pump must not be used in children who have not yet reached adult size.
Estonian: Pumbaga ei tohi manustada muud tüüpi insuliini ja seda ei tohi kasutada lastel, kes ei ole veel kehaliselt arengult täiskasvanud.
English: The patient's blood glucose should be tested regularly to find the lowest effective dose.
Estonian: Vähima efektiivse annuse leidmiseks peab regulaarselt määrama patsiendi vere glükoosisisalduse.
English: Insuman Implantable is used in adult patients with type 1 diabetes that cannot be controlled with insulin given under the skin and who often have episodes of, otherwise unexplained, hyper- or hypoglycaemia (high or low blood glucose levels).
Estonian: Ravimit Insuman Implantable kasutatakse I tüüpi diabeediga täiskasvanud patsientidel, kelle vere glükoosisisaldust ei saa reguleerida naha alla süstitava insuliiniga ning kel on sagedased ja seletamatud hüper- või hüpoglükeemia episoodid (vere suur või väike glükoosisisaldus).
English: Insuman Rapid can also be used for the treatment of hyperglycaemic coma (coma caused by too much blood glucose [sugar]) and ketoacidosis (high levels of ketones [acids] in the blood), and to control blood glucose before, during or after an operation.
Estonian: Insuman Rapidit tohib kasutada ka hüperglükeemilise kooma (kooma, mille põhjuseks on vere liiga suur glükoosisisaldus (nn veresuhkur)) ja ketoatsidoosi (ketoonide ja hapete suur sisaldus veres) raviks ning vere glükoosisisalduse reguleerimiseks enne operatsiooni, selle ajal ja pärast seda.
English: Insuman is used in patients with diabetes (type 1 and 2) who need treatment with insulin.
Estonian: Insumani kasutatakse I ja II tüüpi diabeediga (suhkurtõvega) patsientidel, kes vajavad insuliinravi.
English: It must also not be used in patients who are hypersensitive to titanium alloy, polysulfone or silicone material used in the components of the implanted pump.
Estonian: Seda ei tohi kasutada ka patsiendid, kes on implanteeritavas pumbas sisalduva titaaniumisulami, polüsulfooni või silikooni suhtes ülitundlikud.
English: Insuman was effective for both type 1 and type 2 diabetes.
Estonian: Insuman oli efektiivne nii I kui ka II tüüpi diabeedi korral.
English: Insuman must not be used in people who are hypersensitive (allergic) to human insulin or any of the other ingredients.
Estonian: Insumani ei tohi kasutada patsiendid, kes on iniminsuliini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: • Insuman Basal, an intermediate-acting insulin suspension containing isophane insulin;
Estonian: • keskmise toimeajaga insuliinisuspensioon (Insuman Basal), mis sisaldab isofaaninsuliini;
English: Insuman is a replacement insulin that is similar to the insulin made by the body.
Estonian: Insuman on asendusinsuliin, mis sarnaneb organismis tekkiva insuliiniga.
English: In addition, Insuman Implantable must not be used any other way than as a continuous infusion using the Medtronic MiniMed Implantable Pump.
Estonian: Lisaks ei tohi ravimit Insuman Implantable manustada mingil muul viisil kui pidevinfusioonina Medtronic MiniMedi implanteeritava pumba abil.
English: What benefit has Insuman shown during the studies?
Estonian: Milles seisneb uuringute põhjal Insumani kasulikkus?
English: The CHMP decided that Insuman's benefits are greater than its risks for the treatment of type 1 and type 2 diabetes.
Estonian: Inimravimite komitee otsustas, et Insumani kasulikkus I ja II tüüpi diabeedi ravis on suurem kui sellega kaasnevad riskid.
English: In another study, Insuman Comb 25 was compared with semi-synthetic human insulin in patients with type 1 and type 2 diabetes.
Estonian: Teises uuringus võrreldi I ja II tüüpi diabeediga patsientidel ravimit Insuman Comb 25 poolsünteetilise iniminsuliiniga.
English: The main measure of effectiveness in all studies was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
Estonian: Kõikides uuringutes oli efektiivsuse põhinäitaja glükoseerunud hemoglobiini (HbA1c; hemoglobiin, millele on kinnitunud glükoos) sisalduse muutus veres, mis näitab vere glükoosisisalduse reguleeritavust.
English: See the package leaflet for exact timings.
Estonian: Teave täpse ajastamise kohta on pakendi infolehel.
English: In addition, Insuman Implantable was studied in adult patients with type 1 diabetes.
Estonian: Ravimit Insuman Implantable uuriti ka I tüüpi diabeediga täiskasvanutel.
English: How has Insuman been studied?
Estonian: Kuidas Insumani uuriti?
English: How is Insuman used?
Estonian: Kuidas Insumani kasutatakse?
English: In one of the studies, Insuman was given to patients with type 1 diabetes using an external insulin pump.
Estonian: Ühes uuringus manustati I tüüpi diabeediga patsientidele Insumani välise insuliinipumbaga.
English: These patients received Insuman Implantable as a continuous infusion into the peritoneal cavity.
Estonian: Neile patsientidele manustati ravimit Insuman Implantable kõhuõõnde pidevinfusioonina.
English: The injection site is changed for each injection.
Estonian: Iga süst tehakse eri kohta.
English: • Insuman Comb, which is available in various combinations of fast- and intermediate-acting insulins.
Estonian: • kiiretoimeliste ja keskmise toimeajaga insuliinide eri kombinatsioonid (Insuman Comb).
English: Further information on the way Insuman is given can be found in the Summary of Product Characteristics (also part of the EPAR).
Estonian: Insumani manustamise üksikasjalik teave on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: The Insuman range is comprised of:
Estonian: Ravimisarja Insuman kuuluvad järgmised tooted:
English: It is supplied in vials, cartridges, or pre-filled disposable pens.
Estonian: Insumani turustatakse viaalide, ampullide ja eeltäidetud ühekordsete pensüstaldena.
English: Insuman Infusat is specially prepared ready to be used as a continuous infusion under the skin using an external portable infusion pump.
Estonian: Insuman Infusat on spetsiaalne valmislahus nahaaluseks pidevinfusiooniks, mis manustatakse välise kaasaskantava infusioonipumbaga.
English: How does Insuman work?
Estonian: Kuidas Insuman toimib?
English: What is Insuman used for?
Estonian: Milleks Insumani kasutatakse?
English: • Insuman Rapid, Insuman Infusat and Insuman Implantable, which are fast-acting insulin solutions containing soluble insulin;
Estonian: • lahustuvat insuliini sisaldavad kiiretoimelised insuliinilahused (Insuman Rapid, Insuman Infusat ja Insuman Implantable);